Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects)

Immunology

Volumn 136, Issue 1, 2012, Pages 64-77

  Weber, Cordula ^a   Müller, Christian ^a   Podszuweit, Anja ^a   Montino, Carmen ^a   Vollmer, Jörg ^a   Forsbach, Alexandra ^a  

^a PFIZER INC   (United States)

Author keywords

CD14; SiRNA; TLR3

Indexed keywords

CD14 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

AMINO ACID COMPOSITION; ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; DOWN REGULATION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD14; CELL LINE; DNA, SINGLE-STRANDED; HUMANS; MICE; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9;

EID: 84859361795     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03559.x     Document Type: Article

References (76)

1. Bauer S, Muller T, Hamm S. Pattern recognition by Toll-like receptors. Adv Exp Med Biol 2009; 653:15-34.
2. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 2000; 11:372-8.
3. Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499.
4. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603.
5. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9.
6. Forsbach A, Nemorin JG, Montino C et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008; 180:3729-38.
7. Hornung V, Schlender J, Guenthner-Biller M et al. Replication-dependent potent IFN-α induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol 2004; 173:5935-43.
8. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9.
9. Bauer S, Kirschning CJ, Hacker H et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98:9237-42.
10. Bell JK, Botos I, Hall PR et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A 2005; 102:10976-80.
11. Fukuda K, Watanabe T, Tokisue T et al. Modulation of double-stranded RNA recognition by the N-terminal histidine-rich region of the human toll-like receptor 3. J Biol Chem 2008; 283:22787-94.
12. Kleinman ME, Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452:591-7.
13. Ranjith-Kumar CT, Miller W, Xiong J et al. Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J Biol Chem 2007; 282:7668-78.
14. Yoneda K, Sugimoto K, Shiraki K et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-κB activation and apoptosis. Int J Oncol 2008; 33:929-36.
15. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413:732-8.
16. Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 2007; 178:5200-8.
17. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-50.
18. Kim JY, Choung S, Lee EJ, Kim YJ, Choi YC. Immune activation by siRNA/liposome complexes in mice is sequence-independent: lack of a role for Toll-like receptor 3 signaling. Mol Cells 2007; 24:247-54.
19. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004; 172:6545-9.
20. Kalali BN, Kollisch G, Mages J et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol 2008; 181:2694-704.
21. Okahira S, Nishikawa F, Nishikawa S, Akazawa T, Seya T, Matsumoto M. Interferon-β induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol 2005; 24:614-23.
22. Cho WG, Albuquerque RJ, Kleinman ME et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A 2009; 106:7137-42.
23. Berge M, Bonnin P, Sulpice E et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 2010; 177:3192-201.
24. Czauderna F, Fechtner M, Dames S et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31:2705-16.
25. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8.
26. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431:343-9.
27. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
28. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4:512-20.
29. Baumann CL, Aspalter IM, Sharif O et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010; 207:2689-701.
30. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-κB. J Immunol 2000; 165:3541-4.
31. Lee HK, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006; 24:153-63.
32. de Bouteiller O, Merck E, Hasan UA et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280:38133-45.
33. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7:49-56.
34. Jurk M, Kritzler A, Schulte B et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006; 36:1815-26.
35. Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. Chem Med Chem 2006; 1:1007-14.
36. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002; 293:1364-9.
37. Remaut K, Lucas B, Braeckmans K, Sanders NN, Demeester J, De Smedt SC. Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick? Biochemistry 2006; 45:1755-64.
38. Yasuda K, Rutz M, Schlatter B et al. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur J Immunol 2006; 36:431-6.
39. Zelphati O, Szoka FC Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13:1367-72.
40. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70.
41. Marques JT, Devosse T, Wang D et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 2006; 24:559-65.
42. Zamanian-Daryoush M, Marques JT, Gantier MP et al. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res 2008; 28:221-33.
43. Takahasi K, Yoneyama M, Nishihori T et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 2008; 29:428-40.
44. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32:1958-68.
45. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A, Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004; 16:1143-54.
46. Latz E, Visintin A, Lien E et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002; 277:47834-43.
47. Schmausser B, Andrulis M, Endrich S et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004; 136:521-6.
48. Kajita E, Nishiya T, Miwa S. The transmembrane domain directs TLR9 to intracellular compartments that contain TLR3. Biochem Biophys Res Commun 2006; 343:578-84.
49. Nishiya T, Kajita E, Miwa S, DeFranco AL. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005; 280:37107-17.
50. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like Receptors. J Biol Chem 2004; 279:19008-17.
51. Ranjith-Kumar CT, Duffy KE, Jordan JL et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3. Mol Cell Biol 2008; 28:4507-19.
52. Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34:251-62.
53. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-κB activation. Antisense Nucleic Acid Drug Dev 2001; 11:247-56.
54. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003; 22:621-31.
55. Ulevitch RJ. Toll gates for pathogen selection. Nature 1999; 401:755-6.
56. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008; 20:420-5.
57. Schmitz G, Orso E. CD14 signalling in lipid rafts: new ligands and co-receptors. Curr Opin Lipidol 2002; 13:513-21.
58. Costa LT, Kerkmann M, Hartmann G et al. Structural studies of oligonucleotides containing G-quadruplex motifs using AFM. Biochem Biophys Res Commun 2004; 313:1065-72.
59. Puig M, Grajkowski A, Boczkowska M, Ausin C, Beaucage SL, Verthelyi D. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleic Acids Res 2006; 34:6488-95.
60. Krug A, Rothenfusser S, Hornung V et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 2001; 31:2154-63.
61. Kerkmann M, Rothenfusser S, Hornung V et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170:4465-74.
62. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002; 71:813-20.
63. Rutz M, Metzger J, Gellert T et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004; 34:2541-50.
64. Haas T, Schmitz F, Heit A, Wagner H. Sequence independent interferon-α induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells. Immunology 2009; 126:290-8.
65. Uhlmann E, Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel 2003; 6:204-17.
66. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis eSousa. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31.
67. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003; 24:528-33.
68. Marshall JD, Fearon K, Abbate C et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003; 73:781-92.
69. Zhao Q, Yu D, Agrawal S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett 2000; 10:1051-4.
70. Stunz LL, Lenert P, Peckham D et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002; 32:1212-22.
71. Nakav S, Chaimovitz C, Sufaro Y et al. Anti-inflammatory preconditioning by agonists of adenosine A1 receptor. PLoS ONE 2008; 3:e2107.
72. Mantell SJ, Stephenson PT, Monaghan SM et al. SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg Med Chem Lett 2009; 19:4471-5.
73. Mantell SJ, Stephenson PT, Monaghan SM et al. Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett 2008; 18:1284-7.
74. Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol 2008; 155:463-74.
75. Pinhal-Enfield G, Ramanathan M, Hasko G et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 2003; 163:711-21.
76. Ramakers BP, Riksen NP, Rongen GA, van der Hoeven JG, Smits P, Pickkers P. The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. Cytokine 2006; 35:95-9.